Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Taysha Gene Therapies Inc...

    NASDAQ: TSHA · Real-Time Price · USD
    2.38
    -0.11 (-4.42%)
    At close: Jun 24, 2025, 3:59 PM

    Taysha Gene Therapies Statistics

    Share Statistics

    Taysha Gene Therapies has 261.53M shares outstanding. The number of shares has increased by 1.8% in one year.

    Shares Outstanding

    n/a
    		 261.53M

    Shares Change (YoY)

    n/a
    		 1.8%

    Shares Change (QoQ)

    n/a
    		 0.03%

    Owned by Institutions (%)

    n/a
    		 62.39%

    Shares Floating

    n/a
    		 213.5M

    Failed to Deliver (FTD) Shares

    n/a
    		 994,601

    FTD / Avg. Volume

    n/a
    		 25.76%

    Short Selling Information

    The latest short interest is 31.98M, so 12.23% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 31.98M

    Short % of Shares Out

    n/a
    		 12.23%

    Short % of Float

    n/a
    		 13.73%

    Short Ratio (days to cover)

    n/a
    		 5.49

    Valuation Ratios

    The PE ratio is -4.85 and the forward PE ratio is -6.74. Taysha Gene Therapies's PEG ratio is 0.08.

    PE Ratio

    n/a
    		 -4.85

    Forward PE

    n/a
    		 -6.74

    PS Ratio

    n/a
    		 51.93

    Forward PS

    n/a
    		 1.5

    PB Ratio

    n/a
    		 6.05

    P/FCF Ratio

    n/a
    		 -5.3

    PEG Ratio

    n/a
    		 0.08
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Taysha Gene Therapies.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.42, with a Debt / Equity ratio of 0.88.

    Current Ratio

    n/a
    		 5.42

    Quick Ratio

    n/a
    		 5.42

    Debt / Equity

    n/a
    		 0.88

    Debt / EBITDA

    n/a
    		 -0.72

    Debt / FCF

    n/a
    		 -0.77

    Interest Coverage

    n/a
    		 -896.66

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $114,150.68

    Profits Per Employee

    n/a
    		 $-1,223,260.27

    Employee Count

    n/a
    		 73

    Asset Turnover

    n/a
    		 0.05

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -3.64% in the last 52 weeks. The beta is 1.02, so Taysha Gene Therapies's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.02

    52-Week Price Change

    n/a
    		 -3.64%

    50-Day Moving Average

    n/a
    		 2.31

    200-Day Moving Average

    n/a
    		 1.98

    Relative Strength Index (RSI)

    n/a
    		 42.39

    Average Volume (20 Days)

    n/a
    		 3,861,261

    Income Statement

    In the last 12 months, Taysha Gene Therapies had revenue of 8.33M and earned -89.3M in profits. Earnings per share was -0.36.

    Revenue

    n/a
    		 8.33M

    Gross Profit

    n/a
    		 8.33M

    Operating Income

    n/a
    		 -91.46M

    Net Income

    n/a
    		 -89.3M

    EBITDA

    n/a
    		 -87.95M

    EBIT

    n/a
    		 -89.2M

    Earnings Per Share (EPS)

    n/a
    		 -0.36
    Full Income Statement

    Balance Sheet

    The company has 139.04M in cash and 63.18M in debt, giving a net cash position of 75.86M.

    Cash & Cash Equivalents

    n/a
    		 139.04M

    Total Debt

    n/a
    		 63.18M

    Net Cash

    n/a
    		 75.86M

    Retained Earnings

    n/a
    		 -602.3M

    Total Assets

    n/a
    		 138.36M

    Working Capital

    n/a
    		 98.15M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -81.22M and capital expenditures -374K, giving a free cash flow of -81.6M.

    Operating Cash Flow

    n/a
    		 -81.22M

    Capital Expenditures

    n/a
    		 -374K

    Free Cash Flow

    n/a
    		 -81.6M

    FCF Per Share

    n/a
    		 -0.33
    Full Cash Flow Statement

    Margins

    Gross margin is 85.06%, with operating and profit margins of -1097.55% and -1071.62%.

    Gross Margin

    n/a
    		 85.06%

    Operating Margin

    n/a
    		 -1097.55%

    Pretax Margin

    n/a
    		 -1071.62%

    Profit Margin

    n/a
    		 -1071.62%

    EBITDA Margin

    n/a
    		 -1055.45%

    EBIT Margin

    n/a
    		 -1097.55%

    FCF Margin

    n/a
    		 -979.23%

    Dividends & Yields

    TSHA does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for TSHA is $7, which is 194.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $7

    Price Target Difference

    n/a
    		 194.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 7
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -3.22

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist